Monitoring considerations include: Regular assessment of gastrointestinal tolerability and hydration status Evaluation of any changes in MS symptoms, with low threshold for neurological consultation Glucose monitoring in diabetic patients, with adjustment of other antihyperglycemic agents as needed Periodic assessment of weight loss progress and nutritional adequacy Monitoring for signs of pancreatitis (severe abdominal pain) or gallbladder disease For Wegovy patients, monitoring for depression or suicidal thoughts Patient counseling should address realistic expectations regarding weight loss (typically 15% of body weight over 68 weeks with the 2.4 mg dose plus lifestyle intervention, with less at earlier timepoints), the chronic nature of therapy, and the importance of lifestyle modifications
Stopping GLP-1 treatment too soon can also lead to rebound weight gain or increased blood sugar levels
Bridge program Medicare GLP-1 Bridge: $50/month for eligible Medicare Advantage beneficiaries from July 1, 2026 through December 31, 2027
Embarking on a Weight Loss Journey at Aesthetics MedSpa in Reno, NV Embarking on a weight loss journey is an empowering step towards reclaiming control over your health and well-being
Because bremelanotide acts on desire rather than arousal, the appropriate candidate is a patient whose dysfunction is desire-specific not lubrication, not vascular arousal, and not performance anxiety